Statements (28)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
|
gptkbp:approvalYear |
2001
|
gptkbp:approvedBy |
gptkb:FDA
|
gptkbp:ATCCode |
D11AH02
|
gptkbp:CASNumber |
137071-32-0
|
gptkbp:chemicalFormula |
C43H68N2O11
|
gptkbp:contraindication |
immunocompromised patients
|
gptkbp:drugClass |
immunotherapy
|
gptkbp:form |
gptkb:butter
|
gptkbp:genericName |
gptkb:pimecrolimus
|
https://www.w3.org/2000/01/rdf-schema#label |
Elidel
|
gptkbp:legalStatus |
Rx-only
|
gptkbp:manufacturer |
gptkb:Novartis
|
gptkbp:mechanismOfAction |
immunosuppressant
|
gptkbp:notRecommendedFor |
children under 2 years
|
gptkbp:powers |
1%
|
gptkbp:pregnancyCategory |
C (US)
|
gptkbp:prescriptionStatus |
prescription only
|
gptkbp:riskFactor |
possible increased risk of skin cancer
|
gptkbp:routeOfAdministration |
topical
|
gptkbp:sideEffect |
burning sensation
redness irritation |
gptkbp:storage |
store at room temperature
|
gptkbp:usedFor |
gptkb:eczema
gptkb:atopic_dermatitis |
gptkbp:bfsParent |
gptkb:Valeant_Pharmaceuticals
|
gptkbp:bfsLayer |
6
|